Voyager Therapeutics at CTAD 2026

Nov 16–19, 2026 Boston, MA ~1.7k attendees Website

Voyager Therapeutics takes part in 2 sessions at CTAD 2026 in Boston. Its program centres on tau, with baseline data from a multiple ascending dose study of a C-terminal anti-tau antibody and the first-in-human design for VY1706, a tau-lowering gene therapy that crosses the blood-brain barrier.

Organization	CTAD 2026 Attendance
Voyager Therapeutics Lexington, Massachusetts
voyagertherapeutics.com Biotech Develops an anti-tau antibody and blood-brain-barrier-penetrant gene therapies, including tau-lowering VY1706, for Alzheimer's disease.	Poster Mon Nov 16 – Tue Nov 17 2:00pm Mon – 5:30pm Tue Baseline Characteristics of Participants Enrolled in a Multiple Ascending Dose Study of the C-Terminal Targeting Anti-Tau Antibody VY7523 in Early Alzheimer’s Disease (P054) Anti-amyloid and anti-tau therapies Poster Mon Nov 16 – Tue Nov 17 2:00pm Mon – 5:30pm Tue First-in-Human Study Design of VY1706, a Systemically Administered Blood-Brain Barrier (BBB)-Penetrant Tau Lowering Gene Therapy in Early Alzheimer’s Disease (P055) Anti-amyloid and anti-tau therapies

Organization

CTAD 2026 Attendance

Voyager Therapeutics

Lexington, Massachusetts

voyagertherapeutics.com

Biotech

Develops an anti-tau antibody and blood-brain-barrier-penetrant gene therapies, including tau-lowering VY1706, for Alzheimer's disease.

Poster

Mon Nov 16 – Tue Nov 17
2:00pm Mon – 5:30pm Tue

Baseline Characteristics of Participants Enrolled in a Multiple Ascending Dose Study of the C-Terminal Targeting Anti-Tau Antibody VY7523 in Early Alzheimer’s Disease (P054)

Anti-amyloid and anti-tau therapies

Poster

Mon Nov 16 – Tue Nov 17
2:00pm Mon – 5:30pm Tue

First-in-Human Study Design of VY1706, a Systemically Administered Blood-Brain Barrier (BBB)-Penetrant Tau Lowering Gene Therapy in Early Alzheimer’s Disease (P055)

Anti-amyloid and anti-tau therapies

Instantly find 20 buyers from Voyager Therapeutics

Get a list of who you should contact, their contact info, and what to say.

Totally free and instant, no sign up necessary!

Not affiliated with or endorsed by the CTAD Conference. Organization details are derived from CTAD’s published program, poster list and sponsor page. Submit a correction